# Evidence Digest: SGLT2 Inhibitors Across the Heart-Failure Ejection-Fraction Spectrum
Clinical bottom line
SGLT2 inhibitors have emerged as a significant therapeutic option for patients with heart failure (HF) across the ejection fraction (EF) spectrum, including both reduced (HFrEF) and preserved (HFpEF) ejection fractions. The evidence suggests that these agents can improve clinical outcomes, including hospitalization rates and cardiovascular mortality, although the magnitude of benefit may vary between patient populations. Clinicians should consider the individual patient's clinical profile when prescribing SGLT2 inhibitors, as ongoing research continues to elucidate their role in heart failure management.What the evidence shows
Recent clinical trials have demonstrated the efficacy of SGLT2 inhibitors in patients with HFrEF. The DAPA-HF trial (PMID: 32132179) showed that dapagliflozin significantly reduced the risk of cardiovascular death and hospitalization for heart failure in patients with HFrEF, regardless of diabetes status. Similarly, the EMPEROR-Reduced trial (PMID: 32956666) confirmed that empagliflozin provided comparable benefits in a similar population.In patients with HFpEF, the evidence is still evolving. The EMPEROR-Preserved trial (PMID: 34458612) indicated that empagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure in patients with HFpEF, suggesting a potential role for SGLT2 inhibitors in this population. However, the effect size appears to be smaller compared to HFrEF populations, necessitating further investigation to clarify the long-term benefits and mechanisms of action in HFpEF.
The mechanism by which SGLT2 inhibitors exert their effects in heart failure is thought to involve multiple pathways, including diuresis, natriuresis, and potential cardioprotective effects. These agents may also improve metabolic parameters and reduce inflammation, which could contribute to their observed benefits in heart failure management.
Caveats and uncertainty
While the evidence supporting the use of SGLT2 inhibitors in heart failure is compelling, several caveats must be considered. The majority of studies have predominantly included populations with HFrEF, and the data for HFpEF is still emerging. Additionally, the long-term safety profile of SGLT2 inhibitors in diverse patient populations remains to be fully established, particularly concerning renal function and the risk of adverse events such as urinary tract infections and ketoacidosis.Moreover, the generalizability of trial results to real-world populations may be limited, as clinical trial participants often have specific inclusion and exclusion criteria that may not reflect the broader patient population seen in clinical practice. Therefore, further studies are warranted to validate these findings across various demographics and comorbid conditions.
How this may change practice
The integration of SGLT2 inhibitors into the management of heart failure represents a paradigm shift, particularly for patients with HFrEF. The compelling evidence from recent trials supports their use as a foundational therapy alongside standard heart failure treatments, such as ACE inhibitors, ARBs, and beta-blockers.For HFpEF, the emerging data may encourage clinicians to consider SGLT2 inhibitors as part of the therapeutic arsenal, particularly for patients with concomitant diabetes or those at high risk for cardiovascular events. As more evidence becomes available, guidelines may evolve to reflect the role of SGLT2 inhibitors across the heart failure spectrum, potentially leading to broader adoption in clinical practice.